Literature DB >> 7692307

Cystic fibrosis. Vehicles for gene therapy.

J M Wilson.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7692307     DOI: 10.1038/365691a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


× No keyword cloud information.
  9 in total

1.  Amelioration of collagen-induced arthritis by CD95 (Apo-1/Fas)-ligand gene transfer.

Authors:  H Zhang; Y Yang; J L Horton; E B Samoilova; T A Judge; L A Turka; J M Wilson; Y Chen
Journal:  J Clin Invest       Date:  1997-10-15       Impact factor: 14.808

2.  High-efficiency transfer and expression of AdCMV-p53 in human cervix adenocarcinoma cells induced by subclinical-dose carbon beam radiation.

Authors:  Bing Liu; Hong Zhang; Xiaohong Luo; Yi Xie; Jifang Hao; Qingming Zhou; Xin Duan; Yanling Wang; Weiping Zhao
Journal:  J Cancer Res Clin Oncol       Date:  2008-12-16       Impact factor: 4.553

3.  Development and application of a real-time PCR method for pharmacokinetic and biodistribution studies of recombinant adenovirus.

Authors:  Xian-Xing Xu; Xue Shui; Zhi-Hang Chen; Cheng-Qi Shan; Yu-Nan Hou; Yuan-Guo Cheng
Journal:  Mol Biotechnol       Date:  2009-05-06       Impact factor: 2.695

Review 4.  Cystic fibrosis: a brief look at some highlights of a decade of research focused on elucidating and correcting the molecular basis of the disease.

Authors:  Y H Ko; P L Pedersen
Journal:  J Bioenerg Biomembr       Date:  2001-12       Impact factor: 2.945

5.  Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses.

Authors:  Y Yang; Q Li; H C Ertl; J M Wilson
Journal:  J Virol       Date:  1995-04       Impact factor: 5.103

Review 6.  Autoimmunity, immunologic tolerance, and gene therapy.

Authors:  Y Chen
Journal:  Immunol Res       Date:  1998       Impact factor: 2.829

7.  Phase I trial of recombinant adenovirus gene transfer in lung cancer. Longitudinal study of the immune responses to transgene and viral products.

Authors:  H Gahéry-Ségard; V Molinier-Frenkel; C Le Boulaire; P Saulnier; P Opolon; R Lengagne; E Gautier; A Le Cesne; L Zitvogel; A Venet; C Schatz; M Courtney; T Le Chevalier; T Tursz; J G Guillet; F Farace
Journal:  J Clin Invest       Date:  1997-11-01       Impact factor: 14.808

8.  Immune response to recombinant capsid proteins of adenovirus in humans: antifiber and anti-penton base antibodies have a synergistic effect on neutralizing activity.

Authors:  H Gahéry-Ségard; F Farace; D Godfrin; J Gaston; R Lengagne; T Tursz; P Boulanger; J G Guillet
Journal:  J Virol       Date:  1998-03       Impact factor: 5.103

9.  Cellular Senescence: Ex Vivo p53-Dependent Asymmetric Cell Kinetics.

Authors:  Lakshmi Rambhatla; Shirley A. Bohn; Patrizia B. Stadler; Jonathan T. Boyd; Ronald A. Coss; James L. Sherley
Journal:  J Biomed Biotechnol       Date:  2001
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.